Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dye could sharpen PET scans for recurrent brain cancer

NCT ID NCT04044937

Diagnosis Sponsor: Thomas Hope Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a special dye called fluoroethyltyrosine (FET) can improve PET scans for detecting brain tumors that have come back. 143 people with suspected recurrent brain tumors received an injection of FET before their PET scan. The goal was to see if FET-PET could accurately tell the difference between tumor regrowth and harmless treatment-related changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
F-18 Fluoroethyltyrosine (FET)
What this could lead to
If successful, this imaging agent could help doctors more accurately detect recurrent brain tumors on PET scans, leading to better treatment decisions.
What could go wrong
This is a phase 2 trial, so results are still preliminary. The dye may not prove significantly better than current imaging methods, and its availability may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

143 people

The number who actually took part.

Started

Oct 2018

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 3 years. * Presence or suspicion of intracranial neoplasm in two populations. * Population 1: Patients after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on magnetic resonance imaging (MRI). Three sub-populations will be considered: * Recurrent metastatic lesions. * Recurrent high-grade gliomas (grades 3 and 4). * Recurrent low-grade gliomas (grades 1 and 2). * Population 2: Patients prior to primary treatment with planned biopsy or surgical resection. Exclusion Criteria: * Patient with known incompatibility to PET or computed tomography (CT)/MRI scans. * Patient unlikely to comply with study procedures, restrictions and requirements and judged by the investigator to be unsuitable for study participation. * Sedation or anesthesia can be used for patients who cannot tolerate the exam.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracranial neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioblastoma grade II glioma grade III glioma low grade glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracranial neoplasm Low grade glioma Recurrent glioblastoma Recurrent who grade III glioma Recurrent world health organization (WHO) grade II glioma

Contacts and locations

Locations

  • University of California, San Francisco

    San Francisco, California, 94115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.